



BSW Formulary Update – April 2023

New additions to BSW formulary

- [Contour Next blood glucose test strips](#) Added with **AMBER** TLS, but only for patients under the supervision of the RUH gestational diabetes clinic and using a Contour Next meter connected to the GDM-health gestational diabetes app.

New and Updated Shared Care Agreements and Prescribing Guidance

- **UPDATE** – [Sildenafil for digital ulceration/management of severe Raynaud's phenomenon in adults with Connective Tissue Disease \(unlicensed indication\)](#) Update includes minor reformatting and corrected contact details.
- **CHANGE IN TLS** – [Relugolix-estradiol-norethisterone acetate \(Ryeqo®\)](#) Changed from RED to **AMBER** TLS. After a minimum one month's treatment, Ryeqo may now be prescribed in primary care. Also see **NEW** [BSW Prescribing guidance for relugolix-estradiol-norethisterone acetate \(Ryeqo®\) for treatment of uterine fibroids](#).
- **UPDATE** – [Inclisiran Guidance for Primary Care](#) Update reflects the NHSE change in reimbursement price.
- **UPDATE** – [Initiating SGLT2's in adults with T2D](#) Minor update to formatting.

Removed from BSW formulary

- [Methylcellulose](#) tablets, [Normacol®](#) sachets, [miconazole](#) vaginal cream, [colestipol](#) sachets. Removed from formulary as discontinued by manufacturer.

Aligned on BSW formulary

- [Almotriptan](#) 12.5mg tablets **GREEN** TLS
- [Ganciclovir](#) 0.15% eye gel – **AMBER** TLS (adults)
- [Aciclovir](#) 3% eye ointment – **AMBER** TLS (paeds)
- [Sodium chloride](#) 5% eyedrops and PF eye ointment – **AMBER** TLS
- [Itraconazole](#) oral suspension, aligned with **AMBER** TLS and [Cefixime](#) tablets, [benzathine benzylpenicillin](#) injection, [imipenem/cilastatin](#) injection, [daptomycin](#) injection, [Voractiv®](#) tablets, [moxifloxacin](#) tablets, [famciclovir](#) tablets, [atovaquone](#) oral suspension, all aligned with **RED** TLS. This follows routine review of Chapter 5. Please also see individual formulary entries for more information as some RED TLS antimicrobials are restricted to use **ONLY** after specialist micro advice and may not be routinely stocked within all Trusts.



What the BSW CCG formulary team are currently working on

- Incorporating guanfacine into the existing paediatric ADHD SCA.
- Working with local dermatology teams to review our emollient formulary choices.
- Working with local and regional specialist renal and diabetes teams on prescribing information to support the implementation of finerenone for treating chronic kidney disease in T2D as per NICE [Overview](#) | [Finerenone for treating chronic kidney disease in type 2 diabetes](#) | [Guidance](#) | [NICE](#)

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net